The case for cost-effectively treating cryoglobulinemic vasculitis with interferon-free anti-hepatitis C virus therapy.
about
Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: From interferon-based to direct-acting antivirals era.Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia.Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France.
P2860
The case for cost-effectively treating cryoglobulinemic vasculitis with interferon-free anti-hepatitis C virus therapy.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
The case for cost-effectively ...... nti-hepatitis C virus therapy.
@en
The case for cost-effectively ...... nti-hepatitis C virus therapy.
@nl
type
label
The case for cost-effectively ...... nti-hepatitis C virus therapy.
@en
The case for cost-effectively ...... nti-hepatitis C virus therapy.
@nl
prefLabel
The case for cost-effectively ...... nti-hepatitis C virus therapy.
@en
The case for cost-effectively ...... nti-hepatitis C virus therapy.
@nl
P2860
P50
P356
P1433
P1476
The case for cost-effectively ...... anti-hepatitis C virus therapy
@en
P2093
Guido Granata
Stefania Colantuono
P2860
P356
10.1002/HEP.27600
P407
P577
2015-02-17T00:00:00Z